Results 261 to 270 of about 505,016 (285)
Some of the next articles are maybe not open access.
Baillière's Clinical Endocrinology and Metabolism, 1995
Lipoprotein (a) is similar to low-density lipoprotein but is unique in having an additional apolipoprotein called apolipoprotein (a) (apo(a)) covalently linked to it. apo(a), which is a member of the plasminogen gene superfamily, has a protease domain which cannot be activated to cause fibrinolysis.
A, Piolot, B, Jacotot
+7 more sources
Lipoprotein (a) is similar to low-density lipoprotein but is unique in having an additional apolipoprotein called apolipoprotein (a) (apo(a)) covalently linked to it. apo(a), which is a member of the plasminogen gene superfamily, has a protease domain which cannot be activated to cause fibrinolysis.
A, Piolot, B, Jacotot
+7 more sources
Current Opinion in Lipidology, 2014
Despite being both the longest known and the most prevalent genetic risk marker for atherosclerotic cardiovascular disease (CVD), little progress has been made in agreeing a role for lipoprotein (a) [Lp(a)] in clinical practice and developing therapies with specific Lp(a)-lowering activity.
Durrington, Paul N +3 more
openaire +4 more sources
Despite being both the longest known and the most prevalent genetic risk marker for atherosclerotic cardiovascular disease (CVD), little progress has been made in agreeing a role for lipoprotein (a) [Lp(a)] in clinical practice and developing therapies with specific Lp(a)-lowering activity.
Durrington, Paul N +3 more
openaire +4 more sources
JAMA
This JAMA Insights discusses lipoprotein(a), including factors associated with elevated lipoprotein(a) levels, how to manage them, and atherosclerotic cardiovascular disease risk.
Samia, Mora, Florian, Kronenberg
+6 more sources
This JAMA Insights discusses lipoprotein(a), including factors associated with elevated lipoprotein(a) levels, how to manage them, and atherosclerotic cardiovascular disease risk.
Samia, Mora, Florian, Kronenberg
+6 more sources
Current Opinion in Lipidology, 2016
Purpose of review Currently, different methods for extracorporeal elimination of atherogenic apolipoprotein B100 containing lipoprotein particles are used in clinical practice. Most of them effectively remove both lipoprotein(a) [Lp(a)] and LDL.
Sergei N, Pokrovsky +2 more
openaire +2 more sources
Purpose of review Currently, different methods for extracorporeal elimination of atherogenic apolipoprotein B100 containing lipoprotein particles are used in clinical practice. Most of them effectively remove both lipoprotein(a) [Lp(a)] and LDL.
Sergei N, Pokrovsky +2 more
openaire +2 more sources
Current Opinion in Lipidology, 2014
Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein. The metabolism of this lipoprotein is still not well understood.It has long been known that the plasma concentration of Lp(a) is highly heritable, with its genetic determinants located in the apo(a) locus and regulating the rate of hepatic apo(a) production.
Stefania, Lamon-Fava +2 more
openaire +2 more sources
Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein. The metabolism of this lipoprotein is still not well understood.It has long been known that the plasma concentration of Lp(a) is highly heritable, with its genetic determinants located in the apo(a) locus and regulating the rate of hepatic apo(a) production.
Stefania, Lamon-Fava +2 more
openaire +2 more sources
Lipoprotein(a): A Lipoprotein Whose Time Has Come
Current Treatment Options in Cardiovascular Medicine, 2017Cardiovascular disease is a leading cause of morbidity and mortality in the USA and around the world. While we are now able to achieve significant low-density lipoprotein cholesterol (LDL-C) lowering with current therapies, many patients remain at risk for cardiovascular disease (CVD). Elevated lipoprotein(a) [Lp(a)] has been shown to be an independent
Erik, Kelly, Linda, Hemphill
openaire +2 more sources
Current Opinion in Lipidology, 1999
Lipoprotein(a) is an atherogenic, cholesterol ester-rich lipoprotein of unknown physiological function. The unusual species distribution of lipoprotein(a) and the extreme polymorphic nature of its distinguishing apolipoprotein component, apolipoprotein(a), have provided unique challenges for the investigation of its biochemistry, genetics, metabolism ...
H H, Hobbs, A L, White
openaire +2 more sources
Lipoprotein(a) is an atherogenic, cholesterol ester-rich lipoprotein of unknown physiological function. The unusual species distribution of lipoprotein(a) and the extreme polymorphic nature of its distinguishing apolipoprotein component, apolipoprotein(a), have provided unique challenges for the investigation of its biochemistry, genetics, metabolism ...
H H, Hobbs, A L, White
openaire +2 more sources
European Journal of Cardiovascular Prevention & Rehabilitation, 1994
Our understanding of the pathophysiological role of lipoprotein (a) in cardiovascular disease and its clinical importance has improved, but there are still gaps in our knowledge and analytical performance that hinder the appropriate management of patients.
openaire +2 more sources
Our understanding of the pathophysiological role of lipoprotein (a) in cardiovascular disease and its clinical importance has improved, but there are still gaps in our knowledge and analytical performance that hinder the appropriate management of patients.
openaire +2 more sources
Lipoprotein(a), a Clinically Elusive Lipoprotein Particle
Circulation, 1997The existence of lipoprotein(a) [Lp(a)] in human plasma was first reported by Berg1 in 1963 as an antigen associated with LDL. Berg and Mohr2 also found in family studies that the presence of Lp(a) was genetically determined by an autosomal mode of inheritance. Later studies provided evidence that Lp(a) is a specific class of lipoprotein particles with
Stephen P. Fortmann +1 more
openaire +1 more source